CLDN18.2-positive gastric cancer: what the result can open up

What the CLDN18.2 test measures

CLDN18.2 is a protein assessed in tumor tissue, usually through immunohistochemical staining. A useful report includes the assay, staining intensity and proportion of positive tumor cells. A simple positive label may not establish eligibility for every treatment targeting it.

Different products and studies can use different thresholds. Ask the oncologist which definition applies to the option being considered and whether the original sample is adequate. If repeat tissue is proposed, clarify whether it is needed because of sample quality, timing or a treatment-specific testing requirement.

Sources and references: [1] [2]

Interpret CLDN18.2 alongside the rest of the diagnosis

The stage, HER2 result, PD-L1 score and MSI/MMR status remain relevant. Several positive biomarkers can create a choice between strategies, rather than an instruction to combine every available drug.

Ask which treatment offers the strongest fit for the current line of therapy and why. A biomarker found before any systemic treatment is a different starting point from one found after several regimens. Keep a clear list of previous medicines and the reason each was stopped.

Sources and references: [3] [1] [4]

Where zolbetuximab fits

The US FDA approved zolbetuximab with fluoropyrimidine-platinum chemotherapy for first-line treatment of adults with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. Eligibility includes testing with an appropriate companion assay.

Zolbetuximab is an antibody treatment, given with chemotherapy. Ask how the team will prevent and manage nausea and vomiting and whether your current eating difficulties need attention first. The local indication and supply arrangements should be confirmed by the receiving clinical service.

Sources and references: [1]

Satri-cel now has a specific approved pathway in China

China approved satricabtagene autoleucel, also called satri-cel or CT041, in June 2026. The reported indication covers CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after failure of at least two previous treatment lines.

The eligibility review should name satri-cel and match the gastric or GEJ diagnosis, CLDN18.2 and HER2 results, and previous treatment lines to this indication. Ask the receiving center to confirm the current label, eligibility and whether it can assess you for this product.

Sources and references: [5] [6]

A cell-therapy assessment is more than another infusion

Autologous CAR-T treatment involves the patient's own cells and a specialist treatment process. Assessment needs to cover collection, preparation, treatment before infusion and monitoring afterward. Ask how the cancer will be managed during any waiting period and what would prevent proceeding.

The randomized CT041-ST-01 study supported improved progression-free survival against physician's-choice treatment in a previously treated gastric/GEJ population. Cytokine release syndrome and substantial blood-count suppression were important safety findings. The assessment should address infection support and urgent monitoring, including the period after discharge.

Sources and references: [2] [7]

How trials differ from an approved-product inquiry

Trials may explore a different antibody, an antibody-drug conjugate, a combination or an earlier treatment line. Ask for the study identifier, current recruitment status and eligibility conditions at the proposed hospital. The study team can then confirm whether screening is available for your situation.

Clarify the exact experimental treatment and the comparison group, if any. Ask whether previous CLDN18.2-directed therapy affects eligibility and whether a fresh biopsy is required. Keep a standard-treatment option in view while screening is considered.

Sources and references: [8]

Compare the burden of the feasible options

An antibody-plus-chemotherapy plan, CAR-T treatment and a clinical trial can involve very different time commitments. Compare visits, potential admission, caregiver needs, laboratory monitoring and the plan after returning home. Costs should be itemized against the actual proposed course.

Also ask how response will be measured and what happens if treatment cannot proceed after evaluation. These practical questions help turn a promising test result into a realistic decision. They are particularly important when travel is being considered while the cancer is active.

Sources and references: [8] [1] [2]

Preparing a CLDN18.2 consultation in Shanghai

For a gastric cancer review, our Fudan Cancer Center profile is one relevant Shanghai resource. A request for satri-cel needs a separate check of the treating center's current product pathway and eligibility assessment.

EastMedGo can help organize the pathology blocks information, CLDN18.2 report, HER2 result and treatment timeline. Through contact, tell us which option you are considering. We can coordinate inquiries about clinical assessment, records and practical arrangements before treatment-related travel is booked.

Sources and references: [9] [6]

Common questions